Patients arrive in the electrophysiology lab carrying diagnoses we can see and conditions we often cannot. Heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis (CA) frequently hide behind a presentation of atrial fibrillation, yet both reshape the atrial substrate, the thromboembolic profile, and the durability of the rhythm-control strategies we offer. This roundtable asks a deceptively simple question: if we identified these conditions earlier, before the ablation or the appendage closure, would we make better procedural decisions and achieve better outcomes for our patients?
Using Ultromics’ FDA-cleared EchoGo® platform, which detects HFpEF and cardiac amyloidosis from a single, routinely acquired echocardiographic view, the panel will work through how earlier phenotyping could refine candidate selection, pre-procedure patient management, periprocedural planning, and anticoagulation strategy for AF ablation and LAAC. The discussion is designed to be candid and clinically grounded: where the evidence supports a change in practice, where it does not yet, and what an EP-ready screening workflow would actually look like.
Powered by Ultromics
